BCL2i CLAG-M in R/R Acute Myeloid Leukemia

Inclusion Criteria: * Provision of signed and dated informed consent form. * Ability to understand and stated willingness to comply with all study procedures and availability for the duration of the study. * Adults aged ≥18 years - 80 years. * Patients with documented refractory or relapsed AML: Refractory disease is defined as failure to achieve CR (i.e., \<5% blasts in BM or blood) with or without normal restoration of hematopoiesis (Cri) after at least 1 cycle of intensive induction therapy (or 2 cycles of non-intensive induction). Relapse: Recurrence of disease after achieving remission, meeting one or more of the following criteria: ≥ 5% blasts in the marrow or peripheral blood, extramedullary disease. * Secondary AML arising out of MDS previously treated with HMA, HMA + venetoclax (if \> 3 months from venetoclax exposure), and/or 1 cycle of induction chemotherapy. * Extramedullary AML with marrow involvement is allowed as long as concurrent medullary AML is present. * ECOG performance status ≤ 2. * Participants must have adequate organ function as defined within the protocol. * Human immunodeficiency virus (HIV)-infected participants on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial. Testing is not mandatory. * For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. * Participants with a history of hepatitis C vi…